STOCK WATCH

CLINIGEN is a company that has grown to become one of AIM’s biggest constituents with a market capitalisation north of £1bn.

It calls itself a speciality pharma company, but is actually much more than this.

As well as having an impressive medicine cabinet of niche drugs, it organises access to life-saving medicines that don’t always have regulatory clearance. Shares rose 18.2pc, or 134.5p, to 872p, after it did a deal with Novartis to acquire US rights to a cancer drug.